Sai Life Sciences Limited — PPTs, 15-05-2026: Investor Presentation

Sai Life Sciences posted robust FY26 results with consolidated revenue climbing 29% to ₹2,192 Cr. Both CDMO (up 33% to ₹1,417 Cr) and CRO (up 24% to ₹775 Cr) segments showed strong growth. Profit After Tax (PAT) more than doubled, increasing 109% to ₹355 Cr, while EBITDA rose 56% to ₹661 Cr, with margins expanding to 30.1%.

The company is strategically investing ₹1,100 – 1,300 Cr in FY27, primarily for capacity expansion and new technologies like AI, to meet customer demand and leverage outsourcing trends. Sai is expanding capabilities in next-gen modalities such as Peptides and ADCs, and advancing digital and automation initiatives for improved efficiency.

Recent highlights include deeper strategic engagement with large pharma clients, securing commercial supply qualification from two new customers, and achieving 100% renewable power at its Bidar manufacturing sites. New R&D blocks and a greenfield site acquisition underline infrastructure growth.

Management anticipates a 15-20% revenue CAGR over the next 3-5 years and aims to sustain EBITDA margins of 28-30% for the next 2-3 years, reinforcing confidence in its long-term growth trajectory.